Free Trial
NASDAQ:OCS

Oculis Q3 2025 Earnings Results & Report

Oculis logo
$7.61 -0.03 (-0.43%)
Closing price 03:59 PM Eastern
Extended Trading
$7.63 +0.02 (+0.30%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oculis beat analyst expectations on both earnings and revenue in its Q3 2025 results, released November 10, 2025. The company reported EPS of -$0.40 versus the -$0.50 consensus estimate, while revenue of $305 thousand topped the $225 thousand estimate by $80.00 thousand.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
4:00 PM ET

Oculis EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.50
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Oculis Revenue Results

Actual Revenue
$305 thousand
Expected Revenue
$225 thousand
Beat/Miss
Beat by +$80.00 thousand
YoY Revenue Growth
N/A

Earnings Documents

Oculis Q3 2025 Earnings FAQ

Oculis (NASDAQ:OCS) reported earnings of -$0.40 per share for Q3 2025, beating the consensus estimate of -$0.50. The report was announced on Monday, November 10, 2025.

Oculis reported revenue of $305 thousand for Q3 2025, against a consensus estimate of $225 thousand.

Oculis Earnings Headlines

I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
Oculis Gains FDA IND Clearance for Privosegtor in Acute MS Relapses
See More Oculis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oculis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oculis and other key companies, straight to your email.

About Oculis

Oculis (NASDAQ:OCS) is a clinical-stage biopharmaceutical company developing treatments for eye diseases. Founded in 2017, the company is headquartered in Switzerland and conducts research and development across multiple locations.

Its investigational pipeline includes therapies for conditions such as diabetic macular edema, dry eye disease and optic neuritis. The programs use approaches including topical eye-drop delivery and neuroprotection, with candidates at different stages of clinical development.

Oculis focuses on developing treatments for patients worldwide. Its therapies remain investigational, and the company’s work is centered on advancing candidates through clinical testing and regulatory review.

View Oculis Profile